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Abstract
There are limited data comparing the clinical outcomes between telbivudine and entecavir. We consecutively enrolled 115 telbivudine-naive
and 115 entecavir-naive chronic hepatitis B patients, who were matched for age, sex, hepatitis B e antigen (HBeAg) status and cirrhosis, and
treated for at least 2 years or less than 2 years but had developed resistance. Except for the rate of HBeAg seroconversion, which was
similar, patients in the entecavir group had better clinical outcomes than those in the telbivudine group for alanine aminotransferase
normalization (85.2% vs 78.4%, p <0.048), undetectable HBV DNA (96.5% vs 74.8%, p <0.001), and viral resistance (0.9% vs 21.7%,
p <0.001) after 2 years of treatment, After applying roadmap or super-responders concepts, entecavir still had better outcomes than
telbivudine in undetectable HBV DNA and viral resistance. The cumulative incidence of hepatocellular carcinoma development was similar
between telbivudine-naive and entecavir-naive patients (p 0.565). In renal function analysis, there were signiﬁcantly more patients with
estimated glomerular ﬁltration rate (eGFR) category improvement in both the telbivudine and entecavir groups at year 1 (p 0.006 and
p 0.047, respectively). The rate of virological improvement was signiﬁcantly higher with entecavir than with telbivudine after 2 years of
treatment, whether applying the concepts of roadmap or super-responders. The incidence of hepatocellular carcinoma was similar between
telbivudine and entecavir. Both telbivudine and entecavir were associated with eGFR improvement, especially in patients with renal
insufﬁciency.
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Introduction
Although highly effective vaccines to prevent hepatitis B virus
(HBV) infection have been available since 1982, there are still
more than 350 million chronic carriers, 75% of whom reside in
the Asia Paciﬁc region [1]. These patients are at risk of
developing hepatic decompensation, cirrhosis and hepatocel-
lular carcinoma (HCC). With an expanded range of treatment
options and a substantial improvement in the understanding of
predictors of response to therapy, the management of patients
with chronic hepatitis B (CHB) continues to evolve. Currently,
there are ﬁve oral nucleos(t)ide analogues approved for the
treatment of CHB [2], including three nucleoside analogues
(lamivudine, telbivudine and entecavir) and two nucleotide
analogues (adefovir and tenofovir). Each of these agents is
effective in rapid and profound suppression of viral replication,
facilitating hepatitis B e antigen (HBeAg) seroconversion,
achieving alanine aminotransferase (ALT) normalization, and
improving liver ﬁbrosis. However, there are limited direct
head-to-head trials comparing the different antiviral agents.
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The registration trials of telbivudine and entecavir were
compared with lamivudine, and tenofovir was compared with
adefovir [3–5]. Although our previous study compared the
efﬁcacy of telbivudine and entecavir, there are many limitations
including the small size of patient groups, only 1 year of
comparison, and a heterogeneous baseline [6].
The concept of roadmap, proposed by Keeffe et al. [7], uses
the 24-week virological response to minimize long-term
resistance. From the GLOBE trial, although the resistance
rate at 2 years for telbivudine is 11%, application of a roadmap
concept may reduce this rate. Further analysis from the
GLOBE trial identiﬁed optimal baseline characteristics plus
undetectable HBV DNA at week 24 after treatment (so-called
super-responders) is associated with favourable outcomes
after 2 years of telbivudine treatment. These were: (i)
HBeAg-positive patients with baseline HBV DNA <109 cop-
ies/mL, ALT >2 9 upper limit of normal (ULN) and undetect-
able HBV DNA at week 24; (ii) HBeAg-negative patients with
baseline HBV DNA <107 copies/mL and undetectable serum
HBV DNA at week 24 [8]. However, in real-world clinical
practice, there are limited data to support this concept.
With higher numbers of patients now being treated for
CHB, possible adverse events have gained more attention.
One area of concern is renal function. Adefovir and tenofovir
are both acyclic nucleotide analogues structurally, which have
been shown to be nephrotoxic [9–12]. However, it should be
noted that recent retrospective analyses from clinical studies
demonstrated that long-term telbivudine treatment is associ-
ated with steady improvement in renal function, including in
patients with pre-existing renal disease and those receiving
tenofovir, although the potential mechanisms are unclear [13].
There is no published study indicating this ﬁnding and it is not
known whether long-term treatment with entecavir affects
renal function.
The present study aimed to compare the efﬁcacy and safety
of telbivudine and entecavir in patients who received therapy
for 2 years.
Patients and Methods
Study design and patients
This was a retrospective single-centre match–control study.
Between April 2007 and October 2012, a total of 115 CHB
patients naive-treated with 600 mg telbivudine daily at the
Chang Gung Memorial Hospital, Kaohsiung Medical centre for
at least 2 years or less than 2 years and who had developed
virological resistance were enrolled in this study. The sample
population comprised 88 (77%) men and 27 (23%) women,
with mean age ( SD) 52.9  12.4 years. A total of 28 (24%)
patients were positive for HBeAg and 57 (50%) had cirrhosis.
To compare the efﬁcacy and safety of telbivudine and
entecavir, 115 hepatitis B surface antigen-positive patients
treated with 0.5 mg entecavir daily for at least 2 years were
selected randomly, who matched for age, gender, HBeAg
status and cirrhosis. Of these 230 patients, 186 patents eligible
for this trial were recruited from our previous study
conducted in our centre (telbivudine, n = 94; entecavir,
n = 92, respectively) [6]. The remaining 44 patients who were
treated with telbivudine or entecavir between June 2007 and
October 2010 and ﬁtted the enrolled criteria were added to
the study.
The therapeutic strategy for CHB patients was based on the
criteria approved by the Bureau of National Health Insurance
of Taiwan in 2008. Brieﬂy, the criteria for treatment of CHB
patients are as follows: (i) seropositivity for HBV surface
antigen pulse decompensated liver disease; (ii) elevated ALT
levels  5 9 ULN ( 200 IU/L) for HBeAg-positive patients;
(iii) elevated ALT levels between 2 9 and 5 9 ULN
(80 < ALT <200 IU/L) with HBV DNA levels >105 copies/
mL for HBeAg-positive patients without clinical evidence of
cirrhosis; (iv) elevated ALT levels  2 9 ULN ( 80 IU/L)
with HBV DNA levels >104 copies/mL for HBeAg-negative
patients without clinical evidence of cirrhosis; and (v) HBV
DNA levels >104 copies/mL for patients with clinical evidence
of cirrhosis. Clinical cirrhosis was deﬁned by one of the
followings: (i) ultrasonographic evidence of small liver with
splenomegaly and/or (ii) presence of oesophageal or cardiac
varices. Patients were excluded if they had any evidence of
autoimmune hepatitis or markers of hepatitis C, hepatitis D
and human immunodeﬁciency virus, or patients received
chemotherapy or immunosuppressant agents, and signiﬁcant
intake of alcohol (20 g/day for women; 30 g/day for men).
Patients were followed up every 3 months or less for
clinical assessment, including conventional liver biochemical
tests, a-fetoprotein level, and serological hepatitis B markers
(including HBeAg and antibody to HBeAg). Serial HBV DNA
levels were assessed at baseline, and every 6 months after
treatment. Virological breakthrough was deﬁned as either an
increase of serum HBV DNA of at least 1 log copies/mL from
the nadir for patients with detectable viral load, or serum HBV
DNA >100 copies/mL for patients with undetectable viral load
during treatment [14]. The viral mutational analysis was
determined using nested PCR and direct sequencing, as
described previously [15], at the time of virological break-
through. In addition, ultrasonography was performed for the
surveillance of HCC every 3–6 months. If tumour was
suspected, dynamic computed tomography or magnetic reso-
nance imaging or liver biopsy studies were performed for
conﬁrmation. The diagnosis of HCC was based on the
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guidelines of the American Association for the Study of Liver
Diseases [16]. All patients were treated by 15 experienced
hepatologists at our institution, and were informed of the
purposes of the study, and subsequently gave their written
informed consent. Serum samples were collected from each
patient at the time of their evaluation and frozen at 70°C
until use. The study was approved by the Institutional Review
Board of Chang Gung Memorial Hospital.
Efﬁcacy assessment
Efﬁcacy measures included the proportion of patients with
ALT normalization (<1 9 ULN), HBeAg seroconversion,
undetectable serum HBV DNA (<60 copies/mL) by PCR
assay, and virological resistance at 1 and 2 years, respectively.
Sub-analyses of efﬁcacy outcomes based on super-responder
(for HBeAg-positive patients, baseline HBV DNA <109 copies/
mL, pulse ALT level >2 9 ULN; for HBeAg-negative patients,
baseline HBV DNA <107 copies/mL) [8] and roadmap (unde-
tectable HBV DNA at week 24) [7] concepts were also
performed. Serum HBV DNA levels were quantiﬁed retro-
spectively, if there were no available data, using an Amplicor
HBV monitor (Roche Diagnostic Systems, Branchburg, NJ,
USA), from frozen serum samples, with a lower limit of
quantiﬁcation of 60 copies/mL. For results exceeding the
upper detection limit (6.4 9 108 copies/mL), dilution was
performed.
Furthermore, the incidence of HCC was analysed in
patients excluding HCC development at baseline or within
1 year after treatment.
Safety assessment
The safety assessment aimed to measure the change of renal
function during treatment. Renal function was assessed by the
change of serum creatinine and estimated glomerular ﬁltration
rate (eGFR) from baseline to 1 and 2 years after treatment.
The eGFR was calculated using the Modiﬁcation of Diet in
Renal Disease formula: eGFR = 186 9 (creatinine) – 1.154 9
(age) – 0.203 9 0.472 (if female) [17]. The change of eGFR
frombaseline by baseline eGFR categories (<60, 60–90,>90 mL/
min/1.73 m2) was analysed, especially the percentage of patients
shifting from 60–90 to >90 mL/min/1.73 m2 was assessed.
Missing data were handled as last observation carried forward.
Data analysis
Data are presented as means  SD, proportions, or median
(range). Categorical variables were analysed by the chi-square
or Fisher’s exact test and Student’s t test and Mann–Whitney
U test were used to examine continuous variables with normal
and skewed distribution, respectively. The renal function was
compared using the Wilcoxon paired sample and Mann–
Whitney U test for each group and between two groups, and
McNemar test was used for eGFR shift. Covariates with p
value <0.20 in univariate analysis were included in multivariate
analysis using Cox proportional hazards models to determine
whether pretreatment clinical and laboratory factors and
on-treatment factors were signiﬁcant in predicting HBeAg
seroconversion and virological resistance. The cumulative rate
of HBeAg seroconversion, virological resistance, and HCC and
the differences in the curves were analysed using the Kaplan–
Meier method and the log-rank test, respectively. All statistical
analyses were performed using SPSS 17.0 FOR WINDOWS (SPSS
Inc., Chicago, IL, USA). Survival curves were constructed using
SIGMAPLOT 9.0. All p values were derived from two-tailed
tests and a level of <0.05 was accepted as statistically
signiﬁcant.
Results
Clinical characteristics at baseline
The baseline characteristics of the two study groups are
shown in Table 1. The two groups are similar in terms of
serum ALT levels (226.4.  371.6 vs 204.9  294.7 IU/L) and
HBV DNA levels (6.0  1.6 vs 6.0  1.3 log copies/mL).
However, the proportion of subjects positive for HCC is
greater in the telbivudine group (23.5% vs 13.0%, p = 0.041).
The median duration of follow-up was 31 months (mean
30.2 months) and 34 months (mean 36.3 months) in the
telbivudine and entecavir groups, respectively. In the telbivu-
dine group, 115 (100%), 96 (83.5), 40 (34.8%) and 11 (9.6%)
patients were followed up for 1, 2, 3 and 4 years, respectively;
in the entecavir group, 115 (100%), 114 (99.1%), 56 (48.7%)
TABLE 1. Baseline characteristics of study patients
Telbivudine
(n = 115)
Entecavir
(n = 115) p value
Age (years) 52.9  12.4 53.6  12.1 0.672
Gender (male: female) 88:27 88:27 1.000
HBeAg-positive (%) 28 (24.3%) 28 (24.3%) 1.000
ALT (IU/L) 226.8  371.6 204.9  294.7 0.628
ALT >2 9 ULN (%) 68 (59.1%) 69 (60.0%) 0.893
ALT >5 9 ULN (%) 32 (27.8%) 33 (28.7%) 0.884
Liver cirrhosis (%) 57 (49.6%) 57 (49.6%) 1.000
HCC (%) 27 (23.5%) 15 (13.0%) 0.041
HBV DNA (log copies/mL) 6.0  1.6 6.0  1.3 0.915
Creatinine (mg/dL) 1.0  0.5 1.0  0.3 0.398
eGFR stage (%) 0.061
<60 mL/min 12 12
60–90 mL/min 55 65
>90 mL/min 37 19
Diabetes mellitus (%) 17 (14.8%) 15 (13.0%) 0.703
Hypertension (%) 21 (18.3%) 17 (14.8%) 0.478
Data were expressed as mean SD, no (%).
ALT, alanine transaminase; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus;
HCC, hepatocellular carcinoma; Cr, creatinine; eGFR, estimated glomerular
ﬁltration rate; UNL, upper limit of normal.
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and 24 (20.9%) patients were followed up for 1, 2, 3 and
4 years, respectively, at the time of writing.
Comparisons of efﬁcacy at year 2 after treatment
When all the patients receiving telbivudine (n = 115) or
entecavir (n = 115) therapy were included in an inten-
tion-to-treat analysis of efﬁcacy, the cumulative rates of ALT
normalization, HBeAg seroconversion, HBV DNA undetect-
ability and resistance between the telbivudine and entecavir
groups are shown in Fig. 1. There are no signiﬁcant differences
between telbivudine and entecavir groups in HBeAg serocon-
version at year 2 after treatment (46.4% vs 42.9%). The
proportions of ALT normalization and undetectable HBV
DNA are signiﬁcantly greater in the entecavir group than the
telbivudine group at year 2 after treatment (85.2% vs 78.4%
p 0.048; 96.5% vs 74.8%, p <0.001). Twenty-seven patients
developed the telbivudine-resistant mutation of M204I at
different times during the study period: 9 (7.8%) patients at
year 1; 16 (16.7%) patients at year 2 and 2 (5%) patients at year
3. Of 27 resistant patients, 2 developed the second mutation of
L180M. The cumulative rates of resistance were 7.8%, 21.7%
and 24.9% in the telbivudine group at years 1, 2 and 3,
respectively, which was signiﬁcantly greater than in the
entecavir group (0%, 0.9% and 0.9% at years 1, 2 and 3,
respectively, p <0.001). Only one patient developed enteca-
vir-resistant mutations of L180M plus M204V and S202G at
month 18 after treatment.
The outcomes of patients with favourable baseline
(super-responders) proposed by Zeuzem et al. [8]. and
on-treatment parameters (roadmap) by Keeffe et al. [7]. are
shown in Fig. 2 and Fig. 3. For HBeAg seroconversion, there
was a signiﬁcant difference in the telbivudine group compared
with the entecavir group only after applying the
super-responders concept (83.3% vs 41.2% at year 2,
p 0.008). Although the rate of virological resistance in the
telbivudine group decreased from 21.7% to 11.8% and 13.5% at
year 2 after applying super-responders and roadmap concepts,
respectively, it was still signiﬁcantly greater than in the
entecavir group (p 0.003 and p <0.001, respectively).
The efﬁcacy between the two groups according to HBeAg
status is presented in Table 2. The entecavir group showed
signiﬁcantly greater DNA undetectability and lower resistance
both in HBeAg-positive and HBeAg-negative patients after
2 years of treatment.
100%
75%
50%
25%
0%
ALT HBeAg HBV DNA Viral resistance
undetectabilityseroconversionnormalizaƟon
Number of
paƟents
followed up
115 115 28 28 115 115 115 115
0.9
21.7
p < 0.001
p < 0.001
p = 0.048
85.2
78.4
46.2
42.9
74.8
96.5
LdT
ETV
FIG. 1. Comparison of efﬁcacy results between telbivudine and
entecavir at year 2 (the intension-to-treat population).
FIG. 2. Cumulative rate of hepatitis B virus e
antigen (HBeAg) seroconversion between tel-
bivudine and entecavir groups. Roadmap and
super-responders concepts were proposed by
Keeffe et al. [7] and Zeuzem et al. [8].
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To identify risk factors associated with virological resis-
tance, Cox regression analysis with adjustment for baseline
potential confounders (age, sex, HBeAg status, serum ALT
and HBV DNA levels, and categories of liver disease), HBV
DNA levels after 24 weeks of treatment, and antiviral agents
showed that treatment with telbivudine (hazard
ratio = 28.195, 95% CI = 3.822–208.006, p 0.001) and HBV
DNA undetectable after 24-weeks treatment (hazard
ratio = 0.286, 95% CI = 0.123–0.663, p 0.004) were signif-
icantly associated with virological resistance (Table 3).
Furthermore, to identify which factors were independent
predictors for HBeAg seroconversion, Cox regression
analysis with adjustment for host, viral and treatment effects
showed that only baseline ALT >200 IU/L (hazard
ratio = 4.232, 95% CI = 1.705–10.506, p 0.002) was signiﬁ-
cantly associated with HBeAg seroconversion (Table 4).
FIG. 3. Cumulative rate of resistance between
telbivudine and entecavir groups. Roadmap and
super-responders were proposed by Keeffe
et al. [7] and Zeuzem et al. [8].
HBeAg-positive patients HBeAg-negative patients
Telbivudine
(n = 28)
Entecavir
(n = 28) p value
Telbivudine
(n = 87)
Entecavir
(n = 87) p value
ALT normalization 22 (78.6%) 25 (89.3%) 0.275 64 (73.6%) 73 (83.9%) 0.095
HBeAg seroconversion 13 (46.4%) 12 (42.9%) 0.788 N/A N/A N/A
DNA undetectable 17 (60.7%) 26 (92.9%) 0.004 69 (79.3%) 85 (97.7%) <0.001
Resistance 9 (32.1%) 0 (0%) 0.001 16 (18.4%) 1 (1.1%) <0.001
ALT, alanine aminotransferase; N/A, not applicable.
TABLE 2. Virological, biochemical,
and serological responses after
2 years of therapy according to hep-
atitis B early antigen (HBeAg) sero-
status (the intention-to treat
population)
Univariate Multivariate
Variable Comparison HR (95% CI) p value HR (95% CI) p value
Age (years) 5>50 vs  50 1.463 (0.644–3.321) 0.363
Sex Male vs female 1.091 (0.442–2.690) 0.899
ALT (IU/L) >80 vs  80 0.880 (0.416–1.860) 0.737
HBeAg Positive vs negative 1.833 (0.846–3.973) 0.125 1.038 (0.447–2.408) 0.931
Cirrhosis Yes v. No 0.875 (0.416–1.839) 0.724
Antiviral agents LdT vs ETV 29.776 (4.045–219.197) 0.001 28.195 (3.822–208.006) 0.001
HBV DNA
(log copies/mL)
Per 1 unit increased 1.438 (1.105–1.870) 0.007 1.171 (0.889–1.542) 0.262
HBV DNA
undetectable after
24 weeks of
treatment
Yes vs No 0.220 (0.105–0.463) <0.001 0.286 (0.123–0.663) 0.004
HR, hazard ratio; CI, conﬁdence interval.
TABLE 3. Univariate and multivari-
ate analysis of factors predictive of
virological resistance during telbivu-
dine or entecavir treatment.
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Comparison of HCC development between telbivudine and
entecavir
Of the 188 treated patients without HCC at baseline, HCC was
diagnosed in 15 patients during treatment, ﬁve in the telbivudine
group and ten in the entecavir group. Excluding ﬁve patients who
developed HCC in the 1st year of treatment, 183 patients, 86 in
the telbivudine group and 97 in the entecavir group, were
enrolled for the Kaplan–Meier estimation (Fig. 4). The overall
cumulative incidence ofHCCdevelopmentwas 2.9% and 7.4% at
years 2 and 3, respectively, i.e. 2.5% and 4.1%, respectively, in the
telbivudine group and 3.1% and 7.5%, respectively, in the
entecavir group (p 0.565; Fig. 4a). Further analysis found that
there was no signiﬁcant difference in HCC development
between groups with and without virological resistance
(p 0.315; Fig. 4c). However, the cumulative incidence of HCC
development was signiﬁcantly higher in patients with cirrhosis
than in those patients without cirrhosis (6.9% and 17.7% at years
2 and 3 vs 0%, p <0.001; Fig. 4b).
Estimated renal function assessment between telbivudine
and entecavir
The change of creatinine and eGFR from baseline after 1 or
2 years of treatment in the telbivudine and entecavir groups
are shown in Fig. 5. Both creatinine and eGFR signiﬁcantly
improved in the telbivudine and entecavir groups after 1 year
of treatment (p 0.001 and p <0.001 in the telbivudine group
and p 0.011 and p 0.026 in the entecavir group, respectively),
but no signiﬁcant difference was found at year 2. There was
no signiﬁcant difference in terms of the change of creatinine
and eGFR at year 2 from baseline data between the
telbivudine and entecavir groups. The eGFR shift, according
to three categories (<60, 60–90 and >90 mL/min/1.73 m2),
from baseline to years 1 and 2 are listed in Table 5. There
were signiﬁcantly more patients with eGFR category improve-
ment in the telbivudine and entecavir groups at year 1
(p 0.006 and p 0.047, respectively), but there was no
signiﬁcant improvement at year 2 for either group. Subgroup
analysis of eGFR mean change showed that both telbivu-
dine-treated and entecavir-treated patients with worse base-
line eGFR (<90 mL/min/1.73 m2) had better eGFR
improvement (Fig. 6).
Discussion
This match–control study offers a unique opportunity to
evaluate the efﬁcacy and safety of telbivudine and entecavir in
CHB patients. Our previous study in which telbivudine-naive
and entecavir-naive patients treated for 1 year were compared
indicated that telbivudine-naive patients had higher rates of
HBeAg seroconversion. Meanwhile by combining baseline ALT
and 24-week HBV DNA, telbivudine-naive patients had the
lowest virological resistance [6]. However, there are some
limitations in that study, including the heterogeneous baseline
of the study population, only 1 year of follow-up, and small
population size. This time, except for extension of the study
population and the duration of follow-up, the telbivudine and
entecavir groups were matched by age, sex, HBeAg status and
cirrhosis. To our knowledge, the present study is the ﬁrst
match–control study to compare the efﬁcacy and safety of
telbivudine and entecavir. With regard to efﬁcacy, entecavir
has a better response in ALT normalization, HBV DNA
undetectability and viral resistance after 2 years of treatment.
These results are similar to our previous study which only
indicates the 1-year result [6]. Although a meta-analysis study
indicated that entecavir and tenofovir are the most effective
antiviral agents for CHB [18], there are many limitations in that
study, including only having a comparison for 1-year treatment
and variations in deﬁnitions, measurements, patient charac-
teristics and protocols. In the present match–control,
sing-centre study, most of these limitations are overcome.
Hence, in the present match–control study, we conﬁrm the
poor efﬁcacy of telbivudine compared with entecavir for CHB
patients after 2 years of treatment.
TABLE 4. Univariate and multivari-
ate analysis of factors predictive of
hepatitis B e antigen (HBeAg) sero-
conversion during telbivudine or
entecavir treatment.
Univariate Multivariate
Variable Comparison HR (95% CI) p value HR (95% CI) p value
Age (years)  50 vs. >50 2.116 (0.852–5.257) 0.106 1.890 (0.734–4.878) 0.187
Sex Male vs. Female 1.057 (0.490–2.279) 0.888
ALT (IU/L) >200 vs.  200 4.827 (2.027–11.491) <0.001 4.260 (1.714–10.591) 0.002
HBeAg titre (S/Co)  50 vs. >50 2.429 (1.128–5.230) 0.023 1.826 (0.811–4.111) 0.146
Cirrhosis Yes vs. No 0.698 (0.295–1.655) 0.415
Antiviral agents LdT vs. ETV 1.259 (0.577–2.707) 0.572
HBV DNA
(log copies/mL)
Per 1 unit increased 1.136 (0.867–1.486) 0.355
HBV DNA
undetectable after
24-weeks of
treatment
Yes vs. No 2.721 (1.030–7.188) 0.043 1.866 (0.653–5.335) 0.245
HR, hazard ratio; CI, conﬁdence interval; S/Co, the ratio of the sample (S) to the cut-off (Co).
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It is well known that the concept of roadmap and
super-responders, proposed by Keeffe et al. [7] and Zeuzum
et al. [8], use the 24-week virological response and baseline
HBV DNA plus ALT levels to individualize ongoing manage-
ment in CHB patients to minimize long-term resistance and
improve long-term efﬁcacy. From the present study, we also
compared the telbivudine and entecavir by the concepts of
roadmap and super-responders. Although the 2-year cumula-
tive resistance of telbivudine decreases from 21.7% to 13.5%
and 11.8% after adjusting with roadmap and super-responders
concepts, it is still signiﬁcantly higher than those in the
entecavir group (p <0.001 and p 0.003, respectively). In actual
practice, besides the inherent problems of antiviral therapy,
the cost of long-term drug use, which is associated with patient
compliance, is also an important issue, especially in some Asia
Paciﬁc countries [19]. Therefore, some clinical physicians may
choose telbivudine as the ﬁrst antiviral agent because of its
relatively low price in Asia, and then implement the concepts
of super-responders and roadmap to result in low levels of
resistance and may offer a high probability of HBeAg
seroconversion. However, according to our analysis, despite
applying super-responders and roadmap concepts in telbivu-
dine-naive patients, there is still a signiﬁcant difference in
virological resistance compared with those treated with
entecavir. The potential cost–effect beneﬁt of using telbivudine
as ﬁrst-line agent might be negated by the development of drug
resistance, which would necessitate the addition of adefovir, or
switching to tenofovir.
Notably, the resistance rate seems much higher in the
present study at 2 years after applying either roadmap or
super-responders concepts compared with the GLOBE study.
We could not explain what made the discrepancy between the
present study and the GLOBE study. However, our data was
from actual patients, in which the compliance might be poor
compared with patients in clinical trials. Further studies using
more data of this type are required to conﬁrm this discrep-
ancy.
Our study indicated the higher HBeAg seroconversion in
the telbivudine and entecavir groups (46.4% and 42.9%) after
2 years of treatment. Further analysis found that only baseline
ALT >200 IU/L is an independent predictive factor for HBeAg
seroconversion. The results are compatible with the study by
Liaw [20], which indicates that ALT >200 IU/L reﬂects a more
robust immune clearance of HBV and induces a higher chance
of HBeAg seroconversion during treatment. Another predic-
tive factor is lower titre of HBeAg (<50 S/Co; the ratio of the
sample (S) to the cut-off (Co)) before treatment (p 0.023 by
univariate analysis), although it is not signiﬁcant after multi-
variate analysis. In the present study, the mean HBeAg level
was 294 S/Co (median (interquartile range): 139 (24.0–277.8)),
and our population comprised 17 (30%) HBeAg <50 S/Co and
21 (37.5%) HBeAg <100 S/Co. The high probability of HBeAg
seroconversion noted in the present study can be explained.
Recent studies indicated that pretreatment HBeAg levels and
the changing patterns of quantitative HBeAg resulted in
prediction of an HBeAg response to lamivudine and entecavir
[21,22]. Further studies using quantitative HBeAg to predict a
(a)
(b)
(c)
FIG. 4. Cumulative rate of hepatocellular carcinoma (HCC) devel-
opment between (a) telbivudine and entecavir. (b) liver cirrhosis and
non-liver cirrhosis. (c) resistance and non-resistance groups.
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virological response in telbivudine are needed. To date, the
information from head-to-head studies comparing HBeAg
seroconversion between nucleoside analogues is limited. The
present study ﬁrst indicates that for treatment with telbivudine
or entecavir, baseline ALT remains the strongest predictive
factor for HBeAg seroconversion.
The difference in the rate of HBeAg seroconversion
between the telbivudine and entecavir groups becomes smaller
from year 1 to 2 (46.4% vs 35.7% at year 1 and 46.4% vs 42.9%
at year 2). Although there was a higher incidence of HBeAg
seroconversion in telbivudine-naive patients at year 1, no more
improvement was noted at year 2. In contrast, the improve-
ment in the entecavir group at year 2 shortens the difference
in HBeAg seroconversion. From our previous study [6], mild
improvement of HBeAg seroconversion from 6 to 12 months
after telbivudine treatment was noted; in the present study, no
more improvement is noted from 1 to 2 years. The HBeAg
seroconversion reached a peak at the 1st year, which is
different from the GLOBE trial’s ﬁndings. Our case number is
small (HBeAg-positive, n = 28) and the distribution of pre-
treatment HBeAg titre (S/Co) is wide, which might explain the
high incidence of HBeAg seroconversion in the 1st year and no
improvement in the 2nd year. Further study enrolling more
HBeAg-positive patients is needed to provide the precise
results.
Hepatocellular carcinoma is a potentially fatal consequence
of HBV infection. Increasing evidence suggests that persistent
presence of HBeAg and persistently high serum HBV DNA
levels are associated with increased risk of HCC [23–25].
Antiviral therapy, by suppressing HBV replication and acceler-
ating HBeAg seroconversion, should decrease the risk of
HCC. To date, several studies have examined the preventive
effect of nucleoside analogues. However, there are no studies
directly comparing nucleoside analogues in reduction of the
risk of HCC. The results presented here ﬁrst clearly conﬁrm
that there was no signiﬁcant difference in HCC development
between telbivudine and entecavir-naive patients, even in
patients developing virological resistance. Notably, no one
developed HCC among the non-cirrhotic patients during
34  9.9 (12–55; median 32) months of follow-up after the
initial antiviral therapy. These data are consistent with those of
previous studies. In a systematic review study that pooled 3881
treated patients, HCC occurred in 0.5% nucleos(t)ide ana-
logue-naive patients without cirrhosis during a 46-month
(range 32–108 months) period [26]. A meta-analysis by Sung
TABLE 5. Shift table of estimated glomerular ﬁltration rate (eGFR; MDRD) from baseline to year 1 and 2 with telbivudine or
entecovir therapy (McNemar test)
Baseline
Month 12 (N) Month 24 (N)
eGFR (mL/min/1.73 m2) n (%)
eGFR (mL/min/1.73 m2)
p value n (%)
eGFR (mL/min/1.73 m2)
p value<60 60–90 >90 <60 60–90 >90
LdT <60 11 1 8 2 0.006 8 3 3 2 0.303
60–90 55 0 37 18 38 4 19 15
>90 37 0 10 27 32 0 9 23
Total 103 1 55 47 78 7 31 40
ETV <60 12 8 4 0 0.047 8 6 2 0 0.067
60–90 65 5 42 18 41 2 27 12
>90 19 0 6 13 8 0 3 5
Total 96 13 52 31 57 8 32 17
(a)
(b)
FIG. 5. The mean of creatinine (a) and estimated glomerular ﬁltration
rate (eGFR). (b) between telbivudine and entecavir groups at baseline,
year 1 and year 2.
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et al., with 1267 treated patients (mostly given lamivudine),
indicated that HCC was diagnosed in 1.8% of patients without
cirrhosis [27]. In contrast to non-cirrhotic patients, cirrhotic
patients were still at high risk of developing HCC (6.7% and
17.7% at years 2 and 3, respectively) after telbivudine or
entecavir therapy. These data seemed to be higher than in the
study by Liaw et al. [28]. Further analysis found that in the
present study for the total 114 patients with cirrhosis, 65
(57%) had portal hypertension, as shown by splenomegaly or
oesophageal or gastric varices, which is an independent factor
for HCC development (p 0.036). In addition, the age in our
populations is greater than in the GLOBE study (median, 54 vs
43 years), which might explain the difference. In our analysis,
old age is weakly associated with HCC development (p 0.08).
Therefore, clinical physicians should be very cautious that once
CHB patients develop cirrhosis, strategies to treat as soon as
possible are required to improve the outcomes of chronic
HBV infection.
In recent years, renal function has been an important issue
in patients treated with nucleos(t)ide analogues. Adefovir is
dose limited by tubular toxicity [9], and tenofovir therapy is
associated with increases in creatinine and kidney failure in
human immunodeﬁciency virus/HBV co-infected patients[10–
12]. In contrast, it is mysterious that data from a preclinical
study for telbivudine indicate the improvement of eGFR after
treatment [13]. However, until now, no real-world published
study has proved this ﬁnding. From our analysis, not only
telbivudine but also entecavir improves renal function after
1 year of treatment. Many factors affect renal function,
including history of diabetes, hypertension and refractory
ascites. Further subgroup analysis found that the improvement
in renal function becomes apparent after excluding patients
with a history of diabetes (n = 32), hypertension (n = 38) and
refractory ascites (n = 16), but the results of a predominant
improvement in the 1st year and steady improvement during
the 2nd year, remain. To date, the precise mechanism of these
clinical ﬁndings is missing. The only thing we know is that
nucleoside analogues seem to be beneﬁcial for renal function
compared with nucleotide analogues. Further in vitro and vivo
study should be performed to identify these ﬁndings.
Overall, 28 patients developed drug resistance during the
study period: 27 in the telbivudine group and one in the
entecavir group. For patients who develop virological resis-
tance to telbivudine, current guidelines recommend switching
to or add-on tenofovir or add-on adefovir if tenofovir is not
available [29–31]. Of 27 telbivudine-resistant patients, exclud-
ing two lost to follow-up and three who died due to HCC, 22
patients shifted to or added on other oral antiviral agents:
three shifted to tenofovir; 15 added on adefovir; the other four
shifted to entecavir. Of three patients changing to tenofovir, all
developed HBV DNA undetectability; of 15 add-on adefovir,
12 had undetectable HBV DNA and the other three remain to
have serum HBV DNA detected without any evidence of
mutations; of four shifting to entecavir, only one became HBV
DNA undetectable, two keep low viral loads (533 and
629 copies/mL, respectively), and one developed multi-drug
resistance (A181T + M204I + T184I) at month 18. So far
there is no published study indicating how to treat patients
with telbivudine-resistance. From our follow-up analysis,
comparing add on adefovir which remains 20% of serum
HBV DNA detectable after 1-year rescue therapy, switching to
tenofovir is better for patients with telbivudine resistance.
Further prospective large-scale study is needed to identify this
issue.
Treatment was generally well tolerated in telbivudine-naive
and entecavir-naive patients. No serious adverse events were
recorded during treatment. The incidence of myopathy, char-
acterized by myalgia and elevation of creatine phosphokinase
FIG. 6. Estimated glomerular ﬁltration rate
(eGFR) mean change from baseline to year 1
between telbivudine and entecavir groups
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levels, was 0%. Although three patients suffered from myalgia in
the telbivudine group, the serum creatine phosphokinase levels
were all within the normal range. After receiving analgesia, the
symptom improved without discontinuing telbivudine treatment.
In conclusion, except for the rate of HBeAg seroconversion
being similar, patients in the entecavir group had better clinical
outcomes than those in the telbivudine group after 2 years of
treatment, After applying roadmap or super-responders
concepts, entecavir still had better outcomes than telbivudine.
In addition, the incidence of HCC is similar between telbivu-
dine and entecavir after 2 years of treatment. Finally, we
conﬁrm that both telbivudine and entecavir have an improve-
ment role in renal function, especially in patients with mild
renal insufﬁciency. Further studies will help to understand the
mechanism of this protective effect.
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